Research SummaryKey Findings

What research findings does Tesamorelin have regarding visceral fat and body composition?

Under integrase inhibitor treatment background, improvements in visceral fat, liver fat, and fat distribution indicators. Additionally, research reports: in responders, reduction in visceral fat and waist circumference was observed regardless of presence or absence of neck and back fat accumulation.[1] ↗ [2] ↗

Before ReadingStudy populations, species, formulations and delivery conditions each have a defined scope. Research on an ingredient does not establish that this site's product batches have been validated for efficacy in humans or veterinary use.
i

Currently, 3 original studies related to the theme of this page have been selected. The number of studies includes different designs, populations, or preparations, not commercial clinical efficacy ratings. This page is a usage-oriented positive data selection, not a systematic review or dosing recommendation. Historical studies, combination preparations, and special models are all separately indicated.

Comparison of study design and results

Results from different populations, species, materials, or follow-up times cannot be directly combined. The table below is a comparative summary of published data, not new experimental data.

LiteratureStudy subjects and designObservation and discoveryScope of Explanation
2024 · PMID 38905488Human randomized trial subgroup; HIV-infected individualsUnder integrase inhibitor treatment background, improvements in visceral fat, liver fat, and fat distribution indicators.Small sample subgroup of specific HIV populations.
2023 · PMID 36845310Post hoc analysis of human Phase III trialAmong responders, is there no neck and back fat accumulation, while visceral fat and waist circumference were reduced.Responder analysis; it cannot be inferred that it is effective for all subjects.
2021 · PMID 33756511Human responder analysis of two randomized trialsCT fat density improvement suggests changes in fat tissue quality.Surrogate indicators and responder selection; historical supplement in 2021.

References

Human Study2024REF. 01

What changes occur in visceral fat in HIV under an integrase inhibitor background?

Research Findings

Under integrase inhibitor treatment background, improvements in visceral fat, liver fat, and fat distribution indicators.[1] ↗

Study Design

Human randomized trial subgroup; HIV-infected individuals

Scope & Limitations

Small sample subgroup of specific HIV populations.

View the Article Title and Full Citation＋

Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors.

Russo SC, Ockene MW, Arpante AK, Johnson JE, Lee H, Toribio M, Stanley TL, Hadigan CM, Grinspoon SK, Erlandson KM, Fourman LT.

AIDS (London, England) · Volume/Issue Year 2024
First published 2024-06-20 · PMID 38905488
DOI 10.1097/qad.0000000000003965

Published · Original ResearchPubMed ↗Journal Article ↗
Human Study2023REF. 02

How do responders’ fat distribution and waist circumference change?

Research Findings

Among responders, is there no neck and back fat accumulation, while visceral fat and waist circumference were reduced.[2] ↗

Study Design

Post hoc analysis of human Phase III trial

Scope & Limitations

Responder analysis; it cannot be inferred that it is effective for all subjects.

View the Article Title and Full Citation＋

Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trial.

Rahman F, McLaughlin T, Mesquita P, Morin J, Potvin D, De Chantal M, Aberg JA.

Journal of Clinical and Translational Science · Volume and Issue Year 2023
First published 2022-12-07 · PMID 36845310
DOI 10.1017/cts.2022.515

Published · Original ResearchPubMed ↗Journal Article ↗
Human Study2021 · Historical basic researchREF. 03

Are fat quality and fat quantity the same indicator?

Research Findings

CT fat density improvement suggests changes in fat tissue quality.[3] ↗

Study Design

Human responder analysis of two randomized trials

Scope & Limitations

Surrogate indicators and responder selection; historical supplement in 2021.

View the Article Title and Full Citation＋

Tesamorelin improves fat quality independent of changes in fat quantity.

Lake JE, La K, Erlandson KM, Adrian S, Yenokyan G, Scherzinger A, Dubé MP, Stanley T, Grinspoon S, Falutz J, Mamputu JC, Marsolais C, McComsey GA, Brown TT.

AIDS (London, England) · Volume/Issue Year 2021
First published 2021-07-01 · PMID 33756511
DOI 10.1097/qad.0000000000002897

Published · Original ResearchPubMed ↗Journal Article ↗

Common issues and corresponding evidence

What research findings does Tesamorelin have regarding visceral fat and body composition?＋

Under integrase inhibitor treatment background, improvements in visceral fat, liver fat, and fat distribution indicators. Additionally, research reports: in responders, reduction in visceral fat and waist circumference was observed regardless of presence or absence of neck and back fat accumulation.[1] ↗ [2] ↗

Is visceral fat research the same as general weight-loss research?＋

Not equal. The page data mainly come from HIV-related abnormal fat distribution populations, observing visceral fat, waist circumference, or fat tissue indicators, and cannot be directly extrapolated to whole-body weight loss in healthy people.[1] ↗ [2] ↗

Tesamorelin—these conclusions apply to which study populations?＋

Human randomized trial subgroup; HIV-infected individuals; Post-hoc analysis of Phase III human trials; Responder analysis of two human randomized trials. Small sample subgroup of specific HIV populations.[1] ↗ [2] ↗ [3] ↗

Tesamorelin

Return to catalog specifications and batch file verification entry.

↗